INVENTISBIO CO., LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.71 CNY | +0.46% |
|
+2.11% | -42.47% |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 7,636 | 8,706 | 5,023 | - | - |
| Enterprise Value (EV) 1 | 7,636 | 8,706 | 5,023 | 5,023 | 5,023 |
| P/E ratio | -14 x | -30.7 x | -21.2 x | -21 x | -72.6 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | 46.9 x | 38.9 x | 15.7 x | 11.2 x |
| EV / Revenue | - | 46.9 x | 38.9 x | 15.7 x | 11.2 x |
| EV / EBITDA | - | -31.8 x | -16 x | -25.1 x | -57.7 x |
| EV / FCF | - | -27.7 x | -21.2 x | -12.6 x | -19 x |
| FCF Yield | - | -3.61% | -4.72% | -7.91% | -5.27% |
| Price to Book | - | 4.36 x | 2.54 x | 2.56 x | 3.13 x |
| Nbr of stocks (in thousands) | 575,000 | 575,000 | 576,659 | - | - |
| Reference price 2 | 13.28 | 15.14 | 8.710 | 8.710 | 8.710 |
| Announcement Date | 2/27/23 | 2/6/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 185.5 | 129.2 | 320 | 447.5 |
| EBITDA 1 | - | -273.8 | -314 | -199.7 | -87 |
| EBIT 1 | - | -284 | -288 | -186.9 | -66 |
| Operating Margin | - | -153.06% | -222.91% | -58.39% | -14.75% |
| Earnings before Tax (EBT) 1 | - | -284 | -288 | -186.9 | -67 |
| Net income 1 | -483.5 | -284 | -236.8 | -149.5 | -67 |
| Net margin | - | -153.06% | -183.29% | -46.71% | -14.97% |
| EPS 2 | -0.9500 | -0.4939 | -0.4100 | -0.4150 | -0.1200 |
| Free Cash Flow 1 | - | -314 | -237.2 | -397.1 | -264.9 |
| FCF margin | - | -169.27% | -183.59% | -124.1% | -59.2% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 2/27/23 | 2/6/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -314 | -237 | -397 | -265 |
| ROE (net income / shareholders' equity) | - | -13.5% | -13.9% | -9.73% | -4.2% |
| ROA (Net income/ Total Assets) | - | -13.3% | -15.3% | -12.9% | -3.5% |
| Assets 1 | - | 2,135 | 1,548 | 1,156 | 1,914 |
| Book Value Per Share 2 | - | 3.470 | 3.440 | 3.400 | 2.780 |
| Cash Flow per Share 2 | - | -0.5400 | -0.7400 | -0.3200 | - |
| Capex 1 | - | 6.29 | 9.3 | 13.2 | 60.3 |
| Capex / Sales | - | 3.39% | 7.2% | 4.11% | 13.47% |
| Announcement Date | 2/27/23 | 2/6/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
8.71
CNY
Average target price
18.5
CNY
Spread / Average Target
+112.40%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -42.47% | 694M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- 688382 Stock
- Financials InventisBio Co., Limited
